Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective

Zaid Al-Qurayshi; Jason E Crowther; John B Hamner; Christopher Ducoin; Mary T Killackey; Emad Kandil

doi:10.21873/anticanres.12536

Back

Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective

Journal article

Open access

Peer reviewed

Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective

Zaid Al-Qurayshi, Jason E Crowther, John B Hamner, Christopher Ducoin, Mary T Killackey and Emad Kandil

Anticancer research, Vol.38(5), pp.2897-2901

05/01/2018

DOI: 10.21873/anticanres.12536

PMID: 29715114

Files and links (1)

url

https://doi.org/10.21873/anticanres.12536View

Published (Version of record) Open Access

Abstract

Immunotherapy combined with surgery is associated with better survival than surgery alone in patients with advanced melanoma. This study examined the utilization of immunotherapy in relation to population characteristics and the associated survival benefit. This was a retrospective cohort study utilizing the US National Cancer Database. The study population included 6,165 adult patients (≥18 years) with stage III cutaneous melanoma (median follow-up=32 months). A total of 1,854 patients underwent immunotherapy in addition to surgery, which was associated with a survival benefit over surgery alone (hazard ratio(HR)=0.66, 95% confidence interval(CI)=0.56-0.77, p<0.001). Older age, presence of comorbidities, Medicaid/Medicare insurance, and living in a community with lower average education level were associated with less immunotherapy utilization (all p<0.05). No statistically significant racial disparity in immunotherapy usage was found (p=0.07). Compared to other demographic factors, insurance status was associated with the greatest disparities in immunotherapy utilization and mortality for patients who underwent surgery for advanced melanoma.

Adult

Aged

Cohort Studies

Female

Humans

Immunotherapy - statistics & numerical data

Kaplan-Meier Estimate

Male

Melanoma - mortality

Melanoma - therapy

Melanoma, Cutaneous Malignant

Middle Aged

Neoplasm Staging

Proportional Hazards Models

Retrospective Studies

Skin Neoplasms - mortality

Skin Neoplasms - therapy

Treatment Outcome

United States

Details

Title: Subtitle: Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective
Creators: Zaid Al-Qurayshi - Tulane University
Jason E Crowther - Tulane University
John B Hamner - Tulane University
Christopher Ducoin - Tulane University
Mary T Killackey - Tulane University
Emad Kandil - Tulane University
Resource Type: Journal article
Publication Details: Anticancer research, Vol.38(5), pp.2897-2901
DOI: 10.21873/anticanres.12536
PMID: 29715114
ISSN: 0250-7005
eISSN: 1791-7530
Language: English
Date published: 05/01/2018
Academic Unit: Otolaryngology
Record Identifier: 9984702939902771

Metrics

2 Record Views

33 Times Cited - Web of Science

See more details